Juniper Online Journal of Case Studies
ISSN: 2476-1370

Case Study
Volume 15 Issue 2 April 2025
DOI: 10.19080/JOJCS.2025.15.555907

JOJ Case Stud

Pharmacogenomics in Personalized Medicine

Kapil Kalra[1]* and Jyoti Kalra[2]

[1] *Alpine College of Management & Technology, India*

[2] *School of Pharmaceutical Sciences, SGRR University, India*

Submission: April 02, 2025; **Published:** April 10, 2025

***Corresponding author:** Prof (Dr) Kapil Kalra, Alpine College of Management & Technology, Dehradun Uttarakhand, India

Abstract

Pharmacogenomics is the study of how a person's genetic makeup influences their response to medications. This case study explores the application of pharmacogenomic testing in personalizing treatment for a patient with complex health conditions, such as cancer, to enhance drug efficacy and minimize adverse reactions. To explore how Pharmacogenomic testing can guide the pharmacist in adjusting the patient's medication regimen, improving therapeutic outcomes, and minimizing side effects.

Keywords: Pharmacogenomics; Personalized medicine; Genetic variations; Drug metabolism; Therapeutic outcomes; Adverse drug reactions; Genomic sequencing; Precision medicine; Drug efficacy; Bioinformatics; Clinical pharmacogenetics; Genetic testing

Introduction

Pharmacogenomics, the study of how an individual's genetic makeup influences their response to drugs, is a cornerstone of personalized medicine. By integrating genetic information with pharmacological knowledge, pharmacogenomics aims to optimize drug selection and dosing to achieve the best therapeutic outcomes while minimizing adverse effects. This approach is transforming the way healthcare providers tailor treatments for patients, offering a more precise and individualized approach to medicine. Recent advancements in genomic sequencing technologies and bioinformatics tools have led to a better understanding of genetic variations that influence drug metabolism, efficacy, and toxicity. As pharmacogenomics continues to evolve, it has the potential to significantly improve drug development, patient care, and public health. However, challenges such as the need for large-scale clinical trials, regulatory frameworks, and patient education must be addressed to fully realize its potential in routine clinical practice.

Case Presentation

A 58-year-old female patient with breast cancer, diagnosed with HER2-positive breast cancer, has been prescribed a targeted therapy regimen, including trastuzumab (Herceptin). However, she experiences severe side effects, including fatigue, cardiac toxicity, and low white blood cell count after two cycles of the medication.

Initial assessment and medication history

The patient was started on trastuzumab as part of her chemotherapy protocol after her HER2-positive status was confirmed. However, despite the initial positive response, she begins to experience significant side effects, especially cardiac toxicity (a common issue with trastuzumab), and difficulty tolerating chemotherapy.

The medical team needs to determine whether the side effects are due to the drug or other genetic factors, such as her metabolism or genetic variants that affect drug processing.

Introduction of pharmacogenomic testing

The pharmacist, recognizing the potential role of pharmacogenomics in this case, suggests a pharmacogenomic test to analyze the patient's genetic profile. The test focuses on genetic variants that may influence the metabolism and efficacy of the chemotherapy drugs used in her regimen.

Key tests include:

a) **CYP450 Enzyme Testing:** These enzymes are responsible for metabolizing many chemotherapy drugs, including trastuzumab. Variants in these genes may lead to slower metabolism, resulting in drug accumulation and side effects.

b) **Her2 Gene Amplification Test:** Determines whether the patient's HER2 gene is overexpressed, which is necessary for trastuzumab efficacy.

c) **Pharmacokinetic Profile of Trastuzumab:** Identifying how genetic variations might affect the drug's absorption, distribution, metabolism, and excretion in the body.

Findings and Results

The results of the pharmacogenomic tests reveal several key findings:

1. **HER2 Gene Amplification Confirmed:** The patient has a high level of HER2 overexpression, confirming that trastuzumab is an appropriate treatment for HER2-positive breast cancer. Therefore, the issue likely lies in drug side effects, not in drug efficacy.

2. **CYP2D6 Genotype:** The test indicates that the patient has a polymorphism in the **CYP2D6 gene**, which is crucial for metabolizing several chemotherapy drugs. The patient's variant leads to poor metabolism of trastuzumab, resulting in higher drug concentrations in the bloodstream. This genetic variation explains the intense side effects, particularly the cardiac toxicity and immune suppression.

3. **Drug Interaction Risk:** Additionally, the patient is taking an over-the-counter anti-inflammatory drug (NSAID) for pain, which may further inhibit CYP2D6 activity, exacerbating the side effects of trastuzumab.

Pharmacist's role and interventions

Based on the Pharmacogenomic findings, the pharmacist plays a pivotal role in adjusting the patient's treatment regimen:

1. **Alternative Treatment Plan:** The pharmacist recommends modifying the chemotherapy regimen by switching to an alternative medication with a different metabolic pathway, such as **pertuzumab** or **lapatinib**. Both are effective for HER2-positive breast cancer but are metabolized differently and are less likely to cause cardiac toxicity.

2. **Adjusting Dosage:** The pharmacist works with the oncologist to reduce the trastuzumab dose, taking into account the patient's poor CYP2D6 metabolism, which could help reduce drug accumulation and mitigate side effects.

3. **Patient Education:** The pharmacist educates the patient on the genetic factors influencing her drug metabolism, explaining the need to avoid certain medications that might interfere with chemotherapy metabolism. She is also advised on managing side effects, and the pharmacist emphasizes adherence to the revised treatment plan to avoid complications.

4. **Ongoing Monitoring:** The pharmacist sets up regular follow-up appointments to monitor the patient's response to the new treatment, ensuring that drug levels remain within a therapeutic range and side effects are manageable.

5. **Outcomes and benefits of pharmacogenomics**

After adjusting the treatment regimen based on pharmacogenomic insights:

1. **Reduced Side Effects:** The patient experiences a significant reduction in cardiac toxicity and immune suppression. The new regimen is better tolerated, with fewer adverse reactions.

2. **Improved Efficacy:** The patient's breast cancer continues to respond to the targeted therapy, as HER2 overexpression remains unchanged.

3. **Enhanced Patient Satisfaction:** By addressing the underlying genetic causes of side effects, the patient feels more confident in her treatment and is more compliant with her medication regimen.

4. **Better Health Outcomes:** Personalized treatment leads to a more effective therapy with fewer side effects, improving overall quality of life [1-5].

5. **Conclusion**

This case study demonstrates the importance of pharmacogenomics in personalized medicine, particularly in cancer treatment. Pharmacogenomic testing allows healthcare providers, including pharmacists, to tailor medication regimens based on an individual's genetic profile, leading to more effective treatments and minimized adverse effects. By integrating pharmacogenomics into clinical practice, pharmacists can play a crucial role in optimizing therapeutic outcomes, improving patient safety, and advancing the field of precision medicine. In the future, pharmacogenomics will likely become a routine part of treatment planning, ensuring that all patients receive the most appropriate and individualized care possible.

References

1. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. (2011). Pharmacogenetics: From Bench to Byte—An Update of Guidelines. Clinical Pharmacology & Therapeutics 89(5): 662-673.
2. Ayrton J, Flanagan J (2018) Pharmacogenomics in Oncology: Challenges and Opportunities. Cancer Treatment Reviews 70: 53-62.
3. Kamboj M, Aks S (2020) Pharmacogenomics and Precision Medicine: An Overview. Pharmacogenomics Journal 20(3): 263-276.

How to cite this article: Kapil K, Jyoti K. Pharmacogenomics in Personalized Medicine. JOJ Case Stud. 2025; 15(2): 555907.
DOI: 10.19080/JOJCS.2025.15.555907

4. Johnson JA, Cavallari LH (2013) Pharmacogenetics and Pharmacogenomics in the Era of Personalized Medicine. Clinical Pharmacology & Therapeutics 93(4): 517-528.
5. Gerlach J, Moyer A (2017) Genetic Variations and Their Role in Drug Response: Pharmacogenomics Applications. Journal of Clinical Pharmacology 57(9): 1151-1163.